Higher IL-9 Level is Associated with Psoriasis Vulgaris Complicated by Metabolic Syndrome

References

• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi:10.1111/bjd.18245
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/s0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Hao Y, Zhu YJ, Zou S, et al. Metabolic syndrome and psoriasis: mechanisms and future directions. Front Immunol. 2021;12:711060. doi:10.3389/fimmu.2021.711060
   PubMed Web of Science ®Google Scholar
• Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - What is it and how should it be managed? Eur J Prev Cardiol. 2019;26(2_suppl):33–46. doi:10.1177/2047487319886404
   PubMed Web of Science ®Google Scholar
• Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi:10.1371/journal.pone.0181039
   PubMed Web of Science ®Google Scholar
• Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. doi:10.1016/j.jaad.2017.04.1133
   PubMed Web of Science ®Google Scholar
• Liu L, Cai XC, Sun XY, et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. J Eur Acad Dermatol Venereol. 2022;36(11):1969–1979. doi:10.1111/jdv.18296
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562. doi:10.1038/jid.2011.365
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Neuparth MJ, et al. Systemic inflammation and proinflammatory interleukin-17 signalling persist at the end of therapy in patients with metabolic syndrome and psoriasis, reducing the length of remission. Br J Dermatol. 2016;174(2):414–416. doi:10.1111/bjd.14013
   PubMed Web of Science ®Google Scholar
• Snekvik I, Nilsen TIL, Romundstad PR, Saunes M. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway. Br J Dermatol. 2019;180(1):94–99. doi:10.1111/bjd.16885
   PubMed Web of Science ®Google Scholar
• Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One. 2013;8(1):e51752. doi:10.1371/journal.pone.0051752
   PubMed Web of Science ®Google Scholar
• Midde HS, Priyadarssini M, Rajappa M, et al. Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis. Clin Exp Dermatol. 2021;46(1):50–57. doi:10.1111/ced.14335
   PubMed Web of Science ®Google Scholar
• Dalmas E, Rouault C, Abdennour M, et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr. 2011;94(2):450–458. doi:10.3945/ajcn.111.013771
   PubMed Web of Science ®Google Scholar
• Hang H, Yuan S, Yang Q, Yuan D, Liu Q. Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy. Mol Vis. 2014;20:1137–1145.
   PubMed Web of Science ®Google Scholar
• Sun L, Guo X, Qin Y, et al. Serum intestinal metabolites are raised in patients with psoriasis and metabolic syndrome. Clin Cosmet Investig Dermatol. 2022;15:879–886. doi:10.2147/CCID.S351984
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabet Care. 2004;27(6):1487–1495. doi:10.2337/diacare.27.6.1487
   PubMed Web of Science ®Google Scholar
• Zheng Q, Kuai L, Jiang W, et al. Clinical feature, lifestyle behavior and non-communicable diseases comorbidities among psoriasis patients in shanghai: gender disparity analysis based on a cross-sectional study. Clin Cosmet Investig Dermatol. 2022;15:2751–2762. doi:10.2147/ccid.S393697
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Kubatzky KF, Mitra DK. An update on interleukin-9: from its cellular source and signal transduction to its role in immunopathogenesis. Int J Mol Sci. 2019;20(9):1.
   Web of Science ®Google Scholar
• Guilloteau K, Paris I, Pedretti N, et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol. 2010;184(9):5263–5270. doi:10.4049/jimmunol.0902464
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou H, Zheng H, et al. Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation. Autophagy. 2021;17(2):529–552. doi:10.1080/15548627.2020.1725381
   PubMed Web of Science ®Google Scholar
• Cardoso PR, Lima EV, Lima MM, et al. Clinical and cytokine profile evaluation in Northeast Brazilian psoriasis plaque-type patients. Eur Cytokine Netw. 2016;27(1):1–5. doi:10.1684/ecn.2016.0371
   PubMed Web of Science ®Google Scholar
• Michalak-Stoma A, Bartosińska J, Raczkiewicz D, et al. Multiple cytokine analysis of Th1/Th2/Th9/Th17/Th22/Treg cytokine pathway for individual immune profile assessment in patients with psoriasis. Med Sci Monit. 2022;28:e938277. doi:10.12659/msm.938277
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Ferrante A, et al. Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68(8):1922–1931. doi:10.1002/art.39649
   PubMed Web of Science ®Google Scholar
• Varshney P, Parveen R, Khan MA, Kohli S, Agarwal NB. Increased serum interleukin-9 and interleukin-1β are associated with depression in type 2 diabetes patients. Arq Neuropsiquiatr. 2020;78(5):255–261. doi:10.1590/0004-282x20190177
   PubMed Web of Science ®Google Scholar
• Mohammed H, Salloom DF. Evaluation of interleukin-9 serum level and gene polymorphism in a sample of Iraqi type 2 diabetic mellitus patients. Meta Gene. 2021;27:100845. doi:10.1016/j.mgene.2020.100845
   Web of Science ®Google Scholar
• D’Esposito V, Ambrosio MR, Liguoro D, et al. In severe obesity, subcutaneous adipose tissue cell-derived cytokines are early markers of impaired glucose tolerance and are modulated by quercetin. Int J Obes. 2021;45(8):1811–1820. doi:10.1038/s41366-021-00850-1
   Web of Science ®Google Scholar
• Yang Y, Tang S, Zhai C, et al. Interleukin-9 deletion relieves vascular dysfunction and decreases blood pressure via the STAT3 pathway in angiotensin II-treated mice. Mediators Inflamm. 2020;2020:5741047. doi:10.1155/2020/5741047
   PubMed Web of Science ®Google Scholar
• Pilatz A, Hudemann C, Wolf J, et al. Metabolic syndrome and the seminal cytokine network in morbidly obese males. Andrology. 2017;5(1):23–30. doi:10.1111/andr.12296
   PubMed Web of Science ®Google Scholar
• Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA. 2009;106(31):12885–12890. doi:10.1073/pnas.0812530106
   PubMed Web of Science ®Google Scholar
• Ruiz-Romeu E, Ferran M, de Jesús-Gil C, et al. Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A. J Invest Dermatol. 2018;138(3):580–587. doi:10.1016/j.jid.2017.08.048
   PubMed Web of Science ®Google Scholar
• Zhang S, Gang X, Yang S, et al. The alterations in and the role of the Th17/Treg balance in metabolic diseases. Front Immunol. 2021;12:678355. doi:10.3389/fimmu.2021.678355
   PubMed Web of Science ®Google Scholar
• Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287–292. doi:10.1016/j.biopha.2018.02.103
   PubMed Web of Science ®Google Scholar
• Teijeiro A, Garrido A, Ferre A, Perna C, Djouder N. Inhibition of the IL-17A axis in adipocytes suppresses diet-induced obesity and metabolic disorders in mice. Nat Metab. 2021;3(4):496–512. doi:10.1038/s42255-021-00371-1
   PubMedGoogle Scholar
• Park SM, Do-Thi VA, Lee JO, Lee H, Kim YS. Interleukin-9 inhibits lung metastasis of melanoma through stimulating anti-tumor M1 macrophages. Mol Cells. 2020;43(5):479–490. doi:10.14348/molcells.2020.0047
   PubMed Web of Science ®Google Scholar
• Reddy P, Lent-Schochet D, Ramakrishnan N, McLaughlin M, Jialal I. Metabolic syndrome is an inflammatory disorder: a conspiracy between adipose tissue and phagocytes. Clin Chim Acta. 2019;496:35–44. doi:10.1016/j.cca.2019.06.019
   PubMed Web of Science ®Google Scholar
• Castoldi A, Naffah de Souza C, Câmara NO, Moraes-Vieira PM. The macrophage switch in obesity development. Front Immunol. 2015;6:637. doi:10.3389/fimmu.2015.00637
   PubMed Web of Science ®Google Scholar
• Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. doi:10.1038/s41419-022-04523-3
   PubMed Web of Science ®Google Scholar
• Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175(1):25–31. doi:10.1111/cei.12198
   PubMed Web of Science ®Google Scholar
• Hong CH, Chang KL, Wang HJ, Yu HS, Lee CH. IL-9 induces IL-8 production via STIM1 activation and ERK phosphorylation in epidermal keratinocytes: a plausible mechanism of IL-9R in atopic dermatitis. J Dermatol Sci. 2015;78(3):206–214. doi:10.1016/j.jdermsci.2015.03.004
   PubMed Web of Science ®Google Scholar